Journal
CLINICAL COLORECTAL CANCER
Volume 8, Issue 1, Pages 15-21Publisher
CIG MEDIA GROUP, LP
DOI: 10.3816/CCC.2009.n.003
Keywords
5-Fluorouracil; Cetuximab; Dihydropyrimidine dehydrogenase; ERCC1; Irinotecan; Oxaliplatin; Thymidylate synthase; UGT1A1
Categories
Ask authors/readers for more resources
Predicting response and limiting drug-induced toxicity are 2 important challenges faced by clinicians in the treatment of colorectal cancer (CRC). The introduction of genetic testing to individualize treatment regimens will hopefully allow better response prediction and limit drug-induced toxicity leading to improved patient outcomes. This review discusses the role of the predictive genetic tests associated with the major therapeutic agents used in the treatment of CRC and their clinical significance in the determination of patient-specific treatment regimens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available